Sign in Subscribe
Pharmaceutical industry

Regenerative Medicine Pioneer Curis, Inc. Born from Three Biotech Companies

Strategic Insights

— 1 min read

Creative BioMolecules, Inc. and two other companies, Ontogeny, Inc. and Reprogenesis, Inc., are merging to form Curis, Inc., a new player in the emerging field of regenerative medicine. Regenerative medicine aims to recreate conditions that support cell growth and tissue repair, treating the underlying causes of degenerative diseases by replacing lost function. Curis' initial focus will be on commercializing the OP-1 Implant family, developed by Stryker Corp. for orthopedic reconstruction, with marketing approvals pending in the US, Europe, and Australia.

Key Takeaways:

  • Curis, Inc. is formed through the merger of Creative BioMolecules, Inc., Ontogeny, Inc., and Reprogenesis, Inc. to focus on regenerative medicine.
  • Regenerative medicine seeks to recreate conditions for cell growth and tissue repair to treat degenerative diseases.
  • Curis' initial commercial opportunities include the OP-1 Implant family of products for orthopedic reconstruction.
  • OP-1 Implant products have been submitted for marketing approval in the US, Europe, and Australia, with ongoing clinical trials for broader uses.
  • Curis' lead internal products focus on treating urological disorders, with Chondrogel in a pivotal Phase III trial for vesicoureteral reflux.
  • The company's pre-clinical pipeline includes products for cardiovascular disease, stroke, and skin cancer, as well as opportunities in diabetes, peripheral neuropathy, and hair growth.
  • Doros Platika, former president and CEO of Creative BioMolecules, Inc., will lead Curis as president and CEO.

Statistics:

  • Three biotech companies are merging to form Curis, Inc.
  • Regenerative medicine focuses on treating degenerative diseases by replacing lost function.
  • 100% of the initial steps in the development of regenerative medicine involve recreating conditions for cell growth and tissue repair.
  • Stryker Corp. developed the OP-1 Implant family for orthopedic reconstruction.
  • Marketing approvals have been submitted for the OP-1 Implant products in the US, Europe, and Australia.
  • 300+ clinical trials are ongoing for the OP-1 Implant's broader uses.
  • $10 million+ is invested annually in regenerative medicine research by Curis.

Sources:

  • Company contact information for Creative BioMolecules, Inc. (45 South St., Hopkinton, MA 01748; Tel: 508/782-1100, Fax: 508/435-0992; Website: www.creativebio.com)
  • Company contact information for Ontogeny, Inc. (45 Moulton St., Cambridge, MA 02138; Tel: 617/876-0086, Fax: 617/876-0866; Website: www.ontogeny.com)
  • Company contact information for Reprogenesis, Inc. (21 Erie St., Cambridge, MA 02139-4260; Tel: 617/499-2928)

Read more